Mast cell leukemia classification: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (24 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Mast cell leukemia}} | {{Mast cell leukemia}} | ||
{{CMG}};{{AE}}{{NM}} | {{CMG}};{{AE}}{{NM}},{{s.G.}} | ||
==Overview== | ==Overview== | ||
Mast cell leukemia may be classified into two categories based on prognosis | Mast cell leukemia may be classified into two categories based on prognosis to [[leukemic]] and [[Aleukemic leukemia|aleukemic]]. Also, it can be classified to acute or chronic according to the duration of the symptoms. | ||
==Classification== | ==Classification== | ||
*In 2016 the World Health Organization (WHO) changed classification of tumors of hematopoietic and lymphoid tissues.<ref name="ArberOrazi2016">{{cite journal|last1=Arber|first1=D. A.|last2=Orazi|first2=A.|last3=Hasserjian|first3=R.|last4=Thiele|first4=J.|last5=Borowitz|first5=M. J.|last6=Le Beau|first6=M. M.|last7=Bloomfield|first7=C. D.|last8=Cazzola|first8=M.|last9=Vardiman|first9=J. W.|title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia|journal=Blood|volume=127|issue=20|year=2016|pages=2391–2405|issn=0006-4971|doi=10.1182/blood-2016-03-643544}}</ref> | *In 2016 the [[World Health Organization]] ([[World Health Organization|WHO]]) changed classification of tumors of [[hematopoietic]] and [[lymphoid]] [[Tissue (biology)|tissues]].Based on the duration of [[Symptom|symptoms]], mast cell leukemia may be classified into either [[Acute (medicine)|acute]] or [[Chronic (medical)|chronic]].<ref name="SaviniRondoni2015">{{cite journal|last1=Savini|first1=P.|last2=Rondoni|first2=M.|last3=Poletti|first3=G.|last4=Lanzi|first4=A.|last5=Quercia|first5=O.|last6=Soverini|first6=S.|last7=De Benedittis|first7=C.|last8=Musardo|first8=G.|last9=Martinelli|first9=G.|last10=Stefanini|first10=G. F.|title=Serum Total Tryptase Level Confirms Itself as a More Reliable Marker of Mast Cells Burden in Mast Cell Leukaemia (Aleukaemic Variant)|journal=Case Reports in Hematology|volume=2015|year=2015|pages=1–4|issn=2090-6560|doi=10.1155/2015/737302}}</ref><ref name="ArberOrazi2016">{{cite journal|last1=Arber|first1=D. A.|last2=Orazi|first2=A.|last3=Hasserjian|first3=R.|last4=Thiele|first4=J.|last5=Borowitz|first5=M. J.|last6=Le Beau|first6=M. M.|last7=Bloomfield|first7=C. D.|last8=Cazzola|first8=M.|last9=Vardiman|first9=J. W.|title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia|journal=Blood|volume=127|issue=20|year=2016|pages=2391–2405|issn=0006-4971|doi=10.1182/blood-2016-03-643544}}</ref><ref name="Georgin-LavialleLhermitte2012">{{cite journal|last1=Georgin-Lavialle|first1=S.|last2=Lhermitte|first2=L.|last3=Dubreuil|first3=P.|last4=Chandesris|first4=M.-O.|last5=Hermine|first5=O.|last6=Damaj|first6=G.|title=Mast cell leukemia|journal=Blood|volume=121|issue=8|year=2012|pages=1285–1295|issn=0006-4971|doi=10.1182/blood-2012-07-442400}}</ref> | ||
*In the current classification [[Mast cell tumor|mastocytosis]] is a major category. In the last classification [[Mast cell tumor|mastocytosis]] was subtype of major category ([[Myeloproliferative neoplasm|myeloproliferative neoplasms]]).<ref name="ArberOrazi2016" /> | |||
1.[[Skin|Cutaneous]] [[mastocytosis]] (CM) | |||
2.[[Systemic]] [[mastocytosis]] | |||
:*Leukemic variant | ::*Indolent [[systemic]] [[mastocytosis]] (ISM) | ||
::*Circulating mast cells ≥ 10% | ::*[[Smoldering systemic mastocytosis]] (SSM) | ||
::*Bone marrow mast cells ≥ 20% | ::*[[Systemic]] [[mastocytosis]] with an associated [[hematological]] [[neoplasm]] (SM-AHN) | ||
:*Aleukemic variant | ::*Aggressive [[systemic]] [[Mast cell tumor|mastocytosis]] (ASM) | ||
::*Circulating mast cells < 10% | ::*Mast cell leukaemia (MCL) | ||
*Based on the duration of symptoms, mast cell leukemia may be classified into:<ref name="SaviniRondoni2015">{{cite journal|last1=Savini|first1=P.|last2=Rondoni|first2=M.|last3=Poletti|first3=G.|last4=Lanzi|first4=A.|last5=Quercia|first5=O.|last6=Soverini|first6=S.|last7=De Benedittis|first7=C.|last8=Musardo|first8=G.|last9=Martinelli|first9=G.|last10=Stefanini|first10=G. F.|title=Serum Total Tryptase Level Confirms Itself as a More Reliable Marker of Mast Cells Burden in Mast Cell Leukaemia (Aleukaemic Variant)|journal=Case Reports in Hematology|volume=2015|year=2015|pages=1–4|issn=2090-6560|doi=10.1155/2015/737302}}</ref> | 3.[[Mast cell]] [[sarcoma]] (MCS) | ||
:* Acute mast cell leukemia | |||
:* Chronic mast cell leukemia | |||
*Mast cell leukemia may be classified into two categories based on [[prognosis]]:<ref name="Georgin-LavialleLhermitte2012" /> | |||
:*[[Leukemic]] variant | |||
::*Circulating [[Mast cell|mast cells]] ≥ 10% | |||
::*[[Bone marrow]] [[Mast cell|mast cells]] ≥ 20% | |||
:*[[Aleukemic leukemia|Aleukemic]] variant | |||
::*Circulating [[Mast cell|mast cells]] < 10% | |||
*Based on the duration of [[Symptom|symptoms]], mast cell leukemia may be classified into:<ref name="SaviniRondoni2015">{{cite journal|last1=Savini|first1=P.|last2=Rondoni|first2=M.|last3=Poletti|first3=G.|last4=Lanzi|first4=A.|last5=Quercia|first5=O.|last6=Soverini|first6=S.|last7=De Benedittis|first7=C.|last8=Musardo|first8=G.|last9=Martinelli|first9=G.|last10=Stefanini|first10=G. F.|title=Serum Total Tryptase Level Confirms Itself as a More Reliable Marker of Mast Cells Burden in Mast Cell Leukaemia (Aleukaemic Variant)|journal=Case Reports in Hematology|volume=2015|year=2015|pages=1–4|issn=2090-6560|doi=10.1155/2015/737302}}</ref> | |||
:* [[Acute (medicine)|Acute]] mast cell leukemia | |||
:* [[Chronic (medical)|Chronic]] mast cell leukemia | |||
==References== | ==References== | ||
Latest revision as of 19:05, 3 December 2018
|
Mast cell leukemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mast cell leukemia classification On the Web |
|
American Roentgen Ray Society Images of Mast cell leukemia classification |
|
Risk calculators and risk factors for Mast cell leukemia classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2],Sogand Goudarzi, MD [3]
Overview
Mast cell leukemia may be classified into two categories based on prognosis to leukemic and aleukemic. Also, it can be classified to acute or chronic according to the duration of the symptoms.
Classification
- In 2016 the World Health Organization (WHO) changed classification of tumors of hematopoietic and lymphoid tissues.Based on the duration of symptoms, mast cell leukemia may be classified into either acute or chronic.[1][2][3]
- In the current classification mastocytosis is a major category. In the last classification mastocytosis was subtype of major category (myeloproliferative neoplasms).[2]
1.Cutaneous mastocytosis (CM)
- Indolent systemic mastocytosis (ISM)
- Smoldering systemic mastocytosis (SSM)
- Systemic mastocytosis with an associated hematological neoplasm (SM-AHN)
- Aggressive systemic mastocytosis (ASM)
- Mast cell leukaemia (MCL)
- Leukemic variant
- Circulating mast cells ≥ 10%
- Bone marrow mast cells ≥ 20%
- Aleukemic variant
- Circulating mast cells < 10%
References
- ↑ 1.0 1.1 Savini, P.; Rondoni, M.; Poletti, G.; Lanzi, A.; Quercia, O.; Soverini, S.; De Benedittis, C.; Musardo, G.; Martinelli, G.; Stefanini, G. F. (2015). "Serum Total Tryptase Level Confirms Itself as a More Reliable Marker of Mast Cells Burden in Mast Cell Leukaemia (Aleukaemic Variant)". Case Reports in Hematology. 2015: 1–4. doi:10.1155/2015/737302. ISSN 2090-6560.
- ↑ 2.0 2.1 Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W. (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 0006-4971.
- ↑ 3.0 3.1 Georgin-Lavialle, S.; Lhermitte, L.; Dubreuil, P.; Chandesris, M.-O.; Hermine, O.; Damaj, G. (2012). "Mast cell leukemia". Blood. 121 (8): 1285–1295. doi:10.1182/blood-2012-07-442400. ISSN 0006-4971.